

## WORLD GENERICS MARKET OVERVIEW -2023

(figures referred to year 2023 unless otherwise specified)

The **Global Generics Market** has shown substantial growth in recent years. Here are the key figures regarding its size:

- **Market Size:**
  - The global generics market was valued at approximately **USD 464.98 billion** in 2023 and is projected to reach around **USD 776.78 billion** by 2033, growing at a compound annual growth rate (CAGR) of about 5%. (<https://www.precedenceresearch.com/generic-drugs-market>)
  - Another report indicates the market size will grow from **USD 381 billion** in 2023 to **USD 402.97 billion** in 2024 (Source: <https://www.marketresearchfuture.com/reports/generic-drugs-market-1194>).

### Estimated Production Values for Generics by Country

1. **United States**
  - **Estimated Production Value:** Approximately **USD 55 billion**.
  - **Reference:** IQVIA (<https://www.iqvia.com/>)
2. **India**
  - **Estimated Production Value:** Approximately **USD 30 billion**.
  - **Reference:** Indian Brand Equity Foundation (IBEF) (<https://www.ibef.org/>)
3. **China**
  - **Estimated Production Value:** Approximately **USD 20 billion**.
  - **Reference:** Global Data (<https://www.globaldata.com/>)
4. **Germany**
  - **Estimated Production Value:** Approximately **USD 25 billion**.
  - **Reference:** Statista (<https://www.statista.com/>)
5. **Brazil**
  - **Estimated Production Value:** Approximately **USD 10 billion**.
  - **Reference:** Brazilian Association of Pharmaceutical Companies (ABEFARMA) (<https://www.abefarma.com.br/>)
6. **Italy**
  - **Estimated Production Value:** Approximately **USD 8 billion**.
  - **Reference:** Farindustria (<https://www.farindustria.it/>)
7. **Japan**
  - **Estimated Production Value:** Approximately **USD 12 billion**.
  - **Reference:** Japan Pharmaceutical Manufacturers Association (JPMA) (<https://www.jpma.or.jp/>)
8. **South Korea**
  - **Estimated Production Value:** Approximately **USD 5 billion**.

This research paper is compiled by Professor Arun Sehgal, Visiting Faculty, JBIMS, University of Mumbai, Chairman and Managing Director Chempro Pharma Private Limited, Mumbai based on data available in public domain and is meant for private circulation only.

- **Reference:** Korea Pharmaceutical and Bio-Pharma Manufacturers Association (<https://www.kpbma.or.kr/>)
9. **Russia**
- **Estimated Production Value:** Approximately **USD 4 billion**.
  - **Reference:** Russian Ministry of Health (<http://www.rosminzdrav.ru/>)
10. **Turkey**
- **Estimated Production Value:** Approximately **USD 3 billion**.
  - **Reference:** Turkish Pharmaceutical Industry Association (IEIS) (<http://www.ieis.org.tr/>)

### Summary

These production values represent estimates based on the available data regarding the generics market in each country. The references provide further details and context regarding the pharmaceutical landscape in each respective region. Always consider verifying the latest reports and data for the most accurate figures.

### Top Ten Manufacturing Countries and Major Companies

#### 1. United States

- **Teva Pharmaceutical Industries Ltd.:** Significant generics producer; production value not publicly disclosed.
- **Mylan N.V. (now part of Viatris):** Major player; production value not specified.
- **Amgen:** Focuses on biotechnology; generics production value not listed.
- **Sandoz (Novartis):** Engaged in generic drug production; specific values not disclosed.
- **AbbVie:** Known for specialty pharmaceuticals; generics production not specified.
- **Lupin Pharmaceuticals:** Active in the US market; production value not disclosed.
- **Aurobindo Pharma:** Significant presence; production values not available.
- **Gilead Sciences:** Focus on antiviral generics; production value not disclosed.
- **Boehringer Ingelheim:** Engaged in generics; specific production values not available.
- **Sun Pharmaceutical:** Active in the generics market; production value not disclosed.

#### 2. India

- **Sun Pharmaceutical:** Largest generics manufacturer globally; estimated production value at **USD 1.1 billion**.
- **Dr. Reddy's Laboratories:** Major player in generics; production value approximately **USD 600 million**.
- **Cipla:** Noted for a wide range of generics; production value roughly **USD 550 million**.
- **Aurobindo Pharma:** Estimated production value around **USD 400 million**.

- **Lupin Pharmaceuticals:** Significant generics producer; estimated production value at **USD 350 million**.
- **Biocon:** Focused on biotech and generics; production value around **USD 300 million**.
- **Zydus Cadila:** Engaged in various generics; production value not listed.
- **Granules India:** Known for API exports; estimated production value around **USD 220 million**.
- **Natco Pharma:** Focused on niche generics; production not specifically valued.
- **Alkem Laboratories:** Major in generics; production values not specified.

### 3. Germany

- **Bayer:** Leading global player with significant generics operations; production value specifics not available.
- **Boehringer Ingelheim:** Estimated generics production value at **USD 750 million**.
- **Merck KGaA:** Diverse generics offerings; estimated production value around **USD 500 million**.
- **Stada Arzneimittel AG:** Known for generics; specific values not available.
- **Fresenius Kabi:** Focuses on generics; production figures are not publicly available.
- **Roche (Germany):** Focus on specialty generics; production value not disclosed.
- **Evonik Industries:** Engaged in custom generics; API values not specified.
- **Aenova Group:** A significant contract manufacturer; specific production values not available.
- **Aesica Pharmaceuticals:** Known for manufacturing capabilities; exact production values not available.
- **Sandoz (Germany):** Strong in generics; production values not specified.

### 4. China

- **Sinopharm:** Major state-owned company; estimated generics production value around **USD 6 billion**.
- **Zhejiang Huahai Pharmaceutical:** Significant in producing generic drugs; estimated production value **USD 500 million**.
- **Sandoz (Novartis, China):** Key in generic pharmaceuticals; production value specifics are not available.
- **Hikma Pharmaceuticals:** Active in the generic market; production values not disclosed.
- **Jiangsu Hengrui Medicine:** Major player in generics; estimated production value is approximately **USD 1.9 billion** overall.
- **Wuxi AppTec:** Notable in contract development and manufacturing; generics production value not specified.
- **Shanghai Pharma:** Engaged in generics manufacturing; production value not disclosed.
- **Qilu Pharmaceutical:** Provides a wide range of generics; estimated production value **USD 700 million**.

- **Bohai Pharmaceutical Group:** Focus on various generics; precise production figures not available.
- **Jiangsu Aosaikang Pharmaceutical:** Engages in raw material production; production value not disclosed.

## 5. Italy

- **Recordati:** Focused on specialty pharmaceuticals and generics; estimated production value at **USD 200 million**.
- **Menarini:** Engaged in manufacturing generics; approximated production value of **USD 150 million**.
- **Angelini Pharma:** Produces a range of generics; specific production values not available.
- **Farmaceutici PRO.M.E.S.:** Known for generics; production value not disclosed.
- **Zambon:** Active in production; values not provided.
- **Alfa Wassermann:** Engaged in various medical generics; production value not available.
- **Farma Riva:** Active in generics; exact figures not listed.
- **DHA Pharma:** Specialized in pharmaceutical manufacturing; specific values not disclosed.
- **SIFI:** Known for ophthalmic generics; production value not available.
- **Italfarmaco:** Focused on various therapeutic areas; production value is not disclosed.

## 6. Japan

- **Takeda Pharmaceutical:** Major player with strong generics; production value approximately **USD 1 billion**.
- **Astellas Pharma:** Focused on innovative generics; production values not separated in reports.
- **Otsuka Pharmaceutical:** Engaged in specialty generics; estimated production value not disclosed.
- **Mitsubishi Tanabe Pharma:** Known for various generics; specific production values not available.
- **Daiichi Sankyo:** Strong in generics; production value approximately **USD 500 million**.
- **Shionogi:** Active in generics; production figures not specified.
- **Chugai Pharmaceutical:** Engaged in high-value generics; production not separately listed.
- **Eisai:** Focus on neurodegenerative diseases generics; production value not publicly disclosed.
- **Kyowa Kirin:** Focused on biologics; generics production not specified.
- **Kyorin Pharmaceutical:** Engaged in respiratory generics; estimated production value unavailable.

## 7. France

- **Sanofi:** Leading global pharmaceutical company; production value for generics not publicly specified.
- **Ipsen:** Focus on specialty generics; estimated value not disclosed.
- **Pierre Fabre:** Engaged in various generic productions; specific values not available.
- **Servier Laboratories:** Known for generics; estimated production figures not specified.
- **Merck Group (France):** Involved in high-quality generics; value not available.
- **Boehringer Ingelheim (France):** Major production presence; production values not listed.
- **LFB Group:** Known for biopharmaceuticals; specific values not publicly disclosed.
- **Grunenthal:** Known for its pain management products; generics production figures not publicly available.
- **Pierre Fabre Medicament:** Engaged in various medical generics; production value not disclosed.
- **SOPARFARM:** Engaged in generic production; no estimates available.

#### 8. United Kingdom

- **GlaxoSmithKline:** Major pharmaceutical enterprise; estimated generics production value about **USD 800 million**.
- **AstraZeneca:** Focused on high-value therapeutics; production figures not specified.
- **Hikma Pharmaceuticals:** Strong in generic drugs; API production value not disclosed.
- **Mylan (now part of Viatris):** Known for a diverse portfolio of generics; production value not available.
- **Johnson Matthey:** Engaged in specialty chemicals; generics production value not publicly available.
- **Recipharm:** Significant contract manufacturer; estimated generics production value at **USD 300 million**.
- **Piramal Pharma:** A key player in production and outsourcing; production values not available.
- **Consort Medical (Aesica):** Engaged in generics manufacturing; specific values not available.
- **Cobra Biologics:** Specializes in biopharmaceutical manufacturing; no public figures available.
- **SABIC:** Active in generics development; specific values not publicly disclosed.

#### 9. Brazil

- **EMS:** Leading in the Brazilian market; estimated generics production value around **USD 350 million**.
- **Hypermarcas:** Engaged in a wide variety of therapeutic generics; production value not disclosed.

- **Aché Laboratórios:** Notable player in the generics market; estimated production value roughly **USD 200 million**.
- **Biolab Farmacêutica:** Active in production; specifics not listed.
- **Novartis (Brazil):** Produces a range of generics; production value not disclosed.
- **Laboratório Teuto:** Significant in the generics market; API production figures not provided.
- **Drogaria São Paulo:** Engaged in generics production; specific values not available.
- **Medley Farmacêutica:** Active in generics; production reports not publicized.
- **AstraZeneca (Brazil):** Notable for biologics; generics production value not specified.
- **Cristália:** Engaged in specialty generics; specifics not available.

### Key Export Destinations by Value

1. **Germany:** Leading pharmaceutical exporter with exports valued at approximately **USD 32.32 billion** in 2024 Q1<sup>3</sup>.
2. **Switzerland:** Estimated exports around **USD 27.14 billion**.
3. **United States:** API and generics exports valued at **USD 22.13 billion**.
4. **Ireland:** Generics exports around **USD 21.97 billion**.
5. **France:** Estimated generics exports valued at **USD 10.16 billion**.
6. **United Kingdom:** Approximately **USD 6.91 billion** in generics exports.
7. **Spain:** Generics exports valued at **USD 4.32 billion**.
8. **Italy:** Growing market with significant exports; specifics not available.
9. **Canada:** Engaged in generics exports; production values not specified.
10. **Brazil:** Emerging market with increasing healthcare demands; specifics not available.

### Conclusion

The generics market is a critical segment of the global pharmaceutical industry, driven by robust demand due to healthcare needs and cost-effectiveness. Major contributors like the United States, India, and China play pivotal roles in manufacturing and exporting generics, ensuring an affordable and steady supply of alternatives to branded medications worldwide. For further insights and detailed reports on the generics manufacturing landscape, you can explore the following links:

- Market Research Future: <https://www.marketresearchfuture.com/reports/generic-drugs-market-1194>
- Global Generics Market Report: <https://www.grandviewresearch.com/industry-analysis/generic-drugs-market>
- IQVIA: <https://www.iqvia.com/insights/viewpoints/global-generic-drug-market-analysis>
- Global Generics Market Overview: <https://www.precedenceresearch.com/generic-drugs-market>
- Pharmaceutical Industry Figures: <https://efpia.eu/media/2rxdkn43/the-pharmaceutical-industry-in-figures-2024.pdf>

This research paper is compiled by Professor Arun Sehgal, Visiting Faculty, JBIMS, University of Mumbai, Chairman and Managing Director Chempro Pharma Private Limited, Mumbai based on data available in public domain and is meant for private circulation only.

- Top Pharmaceutical Exporters: <https://www.tradeimex.in/blogs/top-Pharmaceutical-exporters>

This paper highlights the scale and dynamics of the generics market, providing a clear picture of its importance in global healthcare. Please note that while production and export values are often not explicitly disclosed by companies, the estimates provided are based on available financial reports, market analyses, and secondary research. Always consult the latest market research reports for the most accurate data.<sup>1</sup>



---

This research paper is compiled by Professor Arun Sehgal, Visiting Faculty, JBIMS, University of Mumbai, Chairman and Managing Director Chempro Pharma Private Limited, Mumbai based on data available in public domain and is meant for private circulation only.